Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
PAT after MI is Rs. 41 crore which is 162% increase
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Difluprednate Ophthalmic Emulsion, 0.05% is a topical corticosteroid that is indicated in the treatment of inflammation and pain associated with ocular surgery
Subscribe To Our Newsletter & Stay Updated